Comparative effects of gentamicin and tobramycin on excretion of N-acetyl-beta-D-glucosaminidase
Sam T. Donta, L A Lembke
Abstract
Sam T. Donta, L A Lembke
Abstract
Patients receiving gentamicin or tobramycin were studied to determine whether there were differences in the urinary excretion of N-acetyl-beta-D-glucosaminidase (NAG) between the two groups. The average daily increases in NAG excretion were significantly higher in the group receiving gentamicin. In individual patients, the best correlation with nephrotoxicity was with high initial rates of NAG excretion. If abnormally high initial rates of increase can serve as a prognosticator of nephrotoxicity, it may be possible to alter aminoglycoside therapy and to avoid renal damage.
OpenAlex reports 13 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Patients receiving gentamicin or tobramycin were studied to determine whether there were differences in the urinary excretion of N-acetyl-beta-D-glucosaminidase (NAG) between the two groups. The average daily increases in NAG excretion were significantly higher in the group receiving gentamicin. In individual patients, the best correlation with nephrotoxicity was with high initial rates of NAG excretion. If abnormally high initial rates of increase can serve as a prognosticator of nephrotoxicity, it may be possible to alter aminoglycoside therapy and to avoid renal damage.
Key concepts: Tobramycin, Gentamicin, Nephrotoxicity, Aminoglycoside, Excretion, Medicine, Internal medicine, Urinary system